Patent US5002869A successfully refreshed from Google Patents.
US5002869A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes
Assignee: Dana Farber Cancer Institute Inc
•
Filing: 1987-11-02
•
Granted: 1991-03-26
•
Expires: 2007-11-02
Abstract
Abstract A monoclonal antibody which binds preferentially to a subset of the human CD8 lymphocyte population whereby to positively and precisely distinguish between cytotoxic effector and supressor effector cells in the CD8 cell population. The monoclonal antibody recognizes a novel epitope of LFA-1 antigen by means of which it can bind CD8 cells which express the eptope on a surface antigen thereof. The CD8 subset cell population to which this anitbody binds preferentially is the CD8 cytotoxic effector population. This selectivity of the monoclonal antibody enables cell sorting, diagnostic and positive therapeutic applications thereof to be utilized.
Inventors
- 👤 Stuart F. Schlossman
- 👤 Chikao Morimoto
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 05:51
CPC Classifications
G; G03; G03G; G03G15/00; G03G15/65; G03G15/6517; G03G15/6526; A; A61; A61P; A61P37/00; A61P37/02; A61P37/06; C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/2839; C07K16/2845; G03G15/14; G03G15/16; G03G15/1695; A61K; A61K38/00; G03G2215/00; G03G2215/00362; G03G2215/00367; G03G2215/00409; G03G2215/00443; G03G2215/00451; G03G2215/00455; G03G2215/00459; G03G2215/00535; G03G2215/00607; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S530/00; Y10S530/808; Y10S530/809
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
53 words
A hybrid cell line derived by hybridoma technique which produces a monoclonal antibody which binds specifically to an epitope identified as the S6F1 epitope on an antigen identified as the LFA-1 antigen and which enables the monoclonal antibody to distinguish between cytotoxic effector cells and suppressor effector cells in human CD8 lymphocyte populations.
Claim 2
Dependent Claim
53 words
A hybrid cell line derived by hybridoma technique which produces a monoclonal antibody which binds specifically to an epitope identified as the S6F1 epitope on an antigen identified as the LFA-1 antigen and which enables the monoclonal antibody to distinguish between cytotoxic effector cells and suppressor effector cells in human CD8 lymphocyte populations.
Claim 3
Dependent Claim
37 words
The hybrid cell line as described in claim 1 wherein said cell line is produced from the spleen cells of mice which were immunized with an immortalized splenocyte population derived from Herpesvirus saimiri infected white lip tamarin.
Claim 4
Dependent Claim
18 words
The hybrid cell line as described in claim 2 which produces mouse IgG, isotype antibody to S6F1 epitope.
Claim 5
Dependent Claim
22 words
The hybrid cell line as described in claim 1 in which said monoclonal antibody producing cells are derived from the murine cells.
Claim 6
Dependent Claim
19 words
The hybrid cell line as described in claim 1 which was derived from a fusion with mouse myeloma cells.
Claim 7
Dependent Claim
33 words
A hybrid cell line produced by hybridoma technique which has the identifying characteristics of the cell line on deposit with the American Type Culture Collection, Rockville, Maryland, having A.T.C.C. Accession No. HB 9579.
Claim 8
Dependent Claim
33 words
A hybrid cell line produced by hybridoma technique which has the identifying characteristics of the cell line on deposit with the American Type Culture Collection, Rockville, Maryland, having A.T.C.C. Accession No. HB 9579.
Claim 9
Dependent Claim
56 words
A monoclonal antibody which specifically binds to an antigen on the surface of a subset of T lymphocyte population, said antigen: (a) being detectible on CD8 cytotoxic effector cells and essentially undetectible on CD8 suppressor effector cells; and (b) defining a cell surface structure comprised of a 180,000 dalton and a 95,000 dalton molecular weight glycoprotein.
Claim 10
Dependent Claim
56 words
A monoclonal antibody which specifically binds to an antigen on the surface of a subset of T lymphocyte population, said antigen: (a) being detectible on CD8 cytotoxic effector cells and essentially undetectible on CD8 suppressor effector cells; and (b) defining a cell surface structure comprised of a 180,000 dalton and a 95,000 dalton molecular weight glycoprotein.
Claim 11
Dependent Claim
18 words
The monoclonal antibody of claim 7 in which said monoclonal antibody binds an epitope on the LFA-1 antigen.
Claim 12
Dependent Claim
35 words
The monoclonal antibody of claim 7 having mouse isotype IgG/which is produced by the cell line having the identifying characteristics of the sample on deposit with the American Type Culture Collection, A.T.C.C. No. HB 9579.
Claim 13
Dependent Claim
46 words
A monoclonal antibody which binds specfically to an epitope on the LFA-1 antigen of T lymphocytes in human peripheral blood and which binds preferentially to CD8 cytotoxic effector cells present in a population of CD8 cytotoxic effector and CD8 suppressor effector cells in peripheral blood lymphocytes.
Claim 14
Dependent Claim
46 words
A monoclonal antibody which binds specfically to an epitope on the LFA-1 antigen of T lymphocytes in human peripheral blood and which binds preferentially to CD8 cytotoxic effector cells present in a population of CD8 cytotoxic effector and CD8 suppressor effector cells in peripheral blood lymphocytes.
Claim 15
Dependent Claim
11 words
The monoclonal antibody of claim 10 which binds the SF61 epitope.
Claim 16
Independent Claim
88 words
A method of distinguishing between cytotoxic effector cells and suppressor effector cells in a sample of human CD8 lymphocyte populations comprising, contacting said sample with a monoclonal antibody identified as the S6F1 monoclonal antibody for a time and under conditions sufficient for the formation of immunological complexes between said S6F1 monoclonal antibody and CD8 cytotoxic effector cells and then detecting the immunological complexes resulting from said contact between said monoclonal antibody and cells in said sample, the cells complexed with said monoclonal antibody being CD8 cytotoxic effector cells.
Claim 17
Independent Claim
88 words
A method of distinguishing between cytotoxic effector cells and suppressor effector cells in a sample of human CD8 lymphocyte populations comprising, contacting said sample with a monoclonal antibody identified as the S6F1 monoclonal antibody for a time and under conditions sufficient for the formation of immunological complexes between said S6F1 monoclonal antibody and CD8 cytotoxic effector cells and then detecting the immunological complexes resulting from said contact between said monoclonal antibody and cells in said sample, the cells complexed with said monoclonal antibody being CD8 cytotoxic effector cells.
Claim 18
Dependent Claim
54 words
The method of claim 12 including the step of labelling said monoclonal antibody with a detectible compound prior to contacting said sample with said monoclonal antibody such that said complexes are labelled with said detectible compound and said complexes, if any, are formed upon the contacting of said sample with said labelled monoclonal antibody.
Claim 19
Dependent Claim
20 words
The method of claim 12 including the step of separating the detected immunological complexes by cell sorting flow cytometric procedures.
Claim 20
Dependent Claim
14 words
The method of claim 13 in which said detectible compound is a fluorescent compound.
Claim 21
Dependent Claim
13 words
The method of claim 13 in which said detectible compound is an enzyme.
Claim 22
Dependent Claim
34 words
A murine monoclonal antibody of the mouse IgG 1 isotype which is specific for an epitope identified as the S6F1 epitope present on the surface of CD8 cytotoxic effector cells in peripheral blood lymphocytes.
Claim 23
Dependent Claim
34 words
A murine monoclonal antibody of the mouse IgG 1 isotype which is specific for an epitope identified as the S6F1 epitope present on the surface of CD8 cytotoxic effector cells in peripheral blood lymphocytes.
Claim 24
Dependent Claim
10 words
The monoclonal antibody of claim 17 in detectibly labelled form.
Claim 25
Dependent Claim
29 words
The monoclonal antibody of claim 18 wherein said label is selected from the group consisting of a dye, a fluorescent compound, a radioactive element and an electron dense element.
Claim 26
Dependent Claim
28 words
The monoclonal antibody of claim 17 in which said monoclonal antibody is coupled to any one of the group consisting of a human therapeutic radioisotope, pharmaceutical and chemotoxin.
Claim 27
Independent Claim
72 words
A method of detecting and measuring, in liquid biological sample, the S6F1 antigen on the surface of CD8 cytotoxic lymphocytes within the CD8 class of lymphocytes comprising contacting said sample with S6F1 antibody conjugated to a detectable label selected from the group consisting of a fluorescent compound, a radioactive element and an enzyme; allowing said conjugated, antibody to bind to said surface antigen; and then detecting and measuring the bound conjugated antibody.
Claim 28
Independent Claim
72 words
A method of detecting and measuring, in liquid biological sample, the S6F1 antigen on the surface of CD8 cytotoxic lymphocytes within the CD8 class of lymphocytes comprising contacting said sample with S6F1 antibody conjugated to a detectable label selected from the group consisting of a fluorescent compound, a radioactive element and an enzyme; allowing said conjugated, antibody to bind to said surface antigen; and then detecting and measuring the bound conjugated antibody.
Claim 29
Dependent Claim
25 words
The method of claim 21 including the step of flow cytometric cell sorting of the CD8 cytotoxic effector lymphocytes bound by said conjugated monoclonal antibody.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-03-25 | 1994-09-24 | 1995-03-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-03-25 | 1998-09-24 | 1999-03-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-03-25 | 2002-09-24 | 2003-03-26 | $7700.00 | Window Closed / Lapsed |